Welcome to our dedicated page for Veradigm news (Ticker: MDRX), a resource for investors and traders seeking the latest updates and insights on Veradigm stock.
Veradigm Inc. (MDRX) is a healthcare technology company that focuses on healthcare data and technology solutions for providers, payers, and biopharma organizations. News about Veradigm often centers on how the company uses its platforms, data, connectivity, and expertise within the Veradigm Network to support clinical, operational, and financial performance in healthcare.
Investors and industry observers following MDRX news can expect updates on business performance, financing, and capital structure, as reflected in Veradigm’s announcements about financial outlooks, cash and debt levels, and debt financing arrangements. The company also issues news about its progress on financial reporting, including the filing of its Annual Report on Form 10-K with restated financial statements and its efforts to become current in SEC filings and pursue relisting on a national stock exchange.
Operational and client-focused news includes case studies and collaborations that highlight Veradigm’s role in value-based care, payer–provider integration, and revenue cycle management. Examples include recognition through a KLAS Points of Light Award for delivering insights at the point of care and announcements about organizations selecting Veradigm Revenue Cycle Services, Coding Services, and related offerings such as Veradigm Revenue Analytics, Veradigm Practice Management, and Veradigm Payerpath.
Veradigm also issues news on product and capability developments, such as applying artificial intelligence to deidentified EHR data to generate real-world evidence for GLP-1 therapies, and on thought leadership initiatives like the Smart Medicine Podcast. Governance and corporate updates, including leadership appointments and amendments to the company’s stockholder rights plan, are additional recurring themes. For a comprehensive view of MDRX-related developments, this news page aggregates these announcements and related coverage in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Veradigm (NASDAQ: MDRX) announced that its solution, Practice Fusion, ranked first in Allergy and Immunology and second in Rheumatology in Black Book’s 2023 Ambulatory EHR by Physician Specialty category. Practice Fusion, designed for independent practices, supports over 31,000 clinicians and facilitates care for 5 million patients monthly. The EHR system enhances operational efficiency through features like clinical charting and e-prescribing. Tom Langan, President and CCO of Veradigm, emphasized the company’s commitment to empowering independent healthcare providers with cost-effective tools and cloud technology.
Veradigm Inc. (NASDAQ: MDRX) announced a delay in filing its Form 10-K due to expanded audit procedures necessitated by internal control deficiencies in revenue recognition. The cumulative revenue impact has escalated from an initial estimate of $20 million to approximately $40 million, which will require restating financial statements for 2021. Nasdaq has notified the company of non-compliance with timely filing requirements, but this has no immediate impact on stock trading. For fiscal 2023, revenue guidance has been revised downward to $615-$635 million, slightly reducing from the previous range. Non-GAAP earnings per share are forecasted to be between $0.80 and $0.90.
Summary not available.
Veradigm Inc. (NASDAQ: MDRX) announced internal control failures related to revenue recognition over the last six quarters due to errors in a software tool implemented for compliance with FASB’s ASC 606 rule. This has resulted in an estimated revenue misstatement of approximately $20 million, impacting reported Operating Income and Net Income, while cash flows remain unaffected. Consequently, the company has filed a Form 12b-25 with the SEC to extend its Form 10-K filing deadline by 15 days. Financial guidance for Fiscal 2023 has been revised, projecting revenue between $625 million and $645 million and Non-GAAP EPS between $0.80 and $0.90.
Veradigm Inc. (NASDAQ: MDRX) has appointed Susan Rodriguez and Shih-Yin Ho, MD, to its Board of Directors. Rodriguez brings over 30 years in the biopharmaceutical sector, currently serving as Chief Commercial Officer at Ardelyx, with prior leadership roles at Tolmar Pharmaceuticals and Abbott Laboratories. Dr. Ho, a digital health entrepreneur, has over 20 years of experience in health information and analytics, previously leading Aetion Inc. and co-founding Last Mile Research. Their expertise aims to enhance Veradigm's efforts in building the Veradigm Network, benefiting stakeholders significantly.
Veradigm, Inc. (NASDAQ: MDRX) will announce its financial results for the three and twelve months ending December 31, 2022, after market hours on March 1, 2023. The company plans to host a conference call at 4:30 p.m. ET to discuss these results. Participants can join via the Investor Relations website or by dialing 877-269-7756 for conference details.
A replay will be available for one year post-call. Veradigm specializes in healthcare technology, providing a network of data-driven solutions.